multiple myeloma: elranatamab as a single-agent therapy compared to car-t therapy
Published 1 year ago • 298 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
4:14
challenges with the real-world use of car-t therapy in multiple myeloma
-
2:27
bms-986393, a novel anti-gprc5d car-t cell therapy, in multiple myeloma
-
3:03
the future of car-t therapy for multiple myeloma
-
1:01
the potentially curative role of car-t therapy in myeloma
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
2:39
a look into the future of multiple myeloma treatment: t-cell redirecting therapies vs autohsct
-
1:38
real world use of car t-cell therapy in multiple myeloma
-
1:38
how to optimize access to car-t cell therapies in multiple myeloma
-
17:55
talquetamab | therapies on the horizon #myeloma
-
31:04
thriving with myeloma: what you should know about care and treatment
-
6:23
how long will i live with multiple myeloma, and is there a cure? #myeloma
-
2:27
horizon scan of car-t in multiple myeloma
-
1:12
remission of multiple myeloma with car t-cell therapy
-
2:40
car t-cell therapy to revolutionize multiple myeloma?
-
1:53
the future of multiple myeloma treatment
-
3:27
car-t cells in myeloma
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
3:09
an overview of the toxicities associated with immunotherapy in multiple myeloma
-
4:04
overcoming challenges in car t-cell therapy for multiple myeloma
-
1:01
car-t: myeloma toxicities
-
4:58
novel immunotherapies transforming r/r myeloma treatment: bispecifics, car-t cells & more
-
4:12
car-t therapy in multiple myeloma: recent updates, clinical trials and future outlooks